"世界の前立腺がん市場見通し2017-2026" 調査データ


▼当市場調査データについて詳細内容・ご購入は下記ページへ▼
世界の前立腺がん市場見通し2017-2026...市場動向/規模/将来展望...

*** 調査レポートのコンテンツ(一部抜粋)***

LINEで送る

1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Futuristic Market Scenario
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Prostate Cancer Market, By Type
5.1 Introduction
5.2 Hormone Sensitive
5.3 Hormone Refractory
6 Global Prostate Cancer Market, By Therapy
6.1 Introduction
6.2 Focal Therapies
6.3 Biologic Therapy
6.4 Cryosurgery
6.5 Immunotherapy
6.5.1 Vaccines
6.6 Therapeutic Vaccines
6.6.1 Provenge (Sipuleucel-T)
6.7 Radiation Therapy
6.7.1 External Beam
6.7.1.1 Stereotactic Body
6.7.1.2 Proton Beam
6.7.1.3 Intensity Modulated
6.7.1.4 3D Conformal
6.7.2 Brachytherapy
6.7.2.1 Temporary
6.7.2.2 Permanent
6.8 Chemotherapy
6.8.1 Vinorelbine
6.8.2 Vinblastine
6.8.3 Taxotere (Docetaxel)
6.8.4 Taxanes
6.8.5 Jevtana (Cabazitaxel)
6.8.6 Etoposide
6.8.7 Cytotoxic Drugs
6.8.8 Carboplatin
6.8.9 Antimetabolites
6.8.10 Anthracyclines
6.8.11 Alkylating Agents
6.9 Surgery
6.9.1 Trans Urethral Resection (TUR)
6.9.2 Radical Prostatectomy
6.9.3 Orchidectomy
6.10 Targeted Therapy
6.10.1 Tyrosine Kinase Inhibitors
6.10.2 Signal Transduction Inhibitor
6.10.3 Monoclonal Antibodies
6.10.4 Apoptosis Inducing Drugs
6.10.5 Angiogenesis Inhibitor
6.11 Bone Metastasis
6.11.1 Zometa (Zoledronic Acid)
6.11.2 Xofigo (Radium 223 Dichloride)
6.11.3 Xgeva (Denosumab)
6.11.4 Alpharadin
6.12 Hormonal Therapy
6.12.1 Aromatase Inhibitors
6.12.2 Estrogen-Receptor Modulators (Serms)
6.12.3 Luteinizing Hormone–Releasing Hormone (LHRH) Analogs
6.12.3.1 Lupron
6.12.3.2 Zoladex
6.12.3.3 Decapeptyl
6.12.3.4 Eligard
6.12.3.5 Vantas
6.12.3.6 Leuplin
6.12.3.7 Trelstar (Triptorelin Pamoate)
6.12.3.8 Firmagon (Degarelix)
6.12.3.9 Casodex (Bicalutamide)
6.12.4 Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists
6.12.4.1 Zytiga
6.12.4.2 Gonax
6.12.4.3 Xtandi (Enzalutamide)
6.12.5 Anti–Androgens
6.12.5.1 Casodex
6.12.5.2 Xtandi or MDV3100
6.12.5.3 Xtandi US or MDV3100
6.12.6 Other Hormonal Therapies
7 Global Prostate Cancer Market, By Diagnostic Technique
7.1 Introduction
7.2 Prostate Specific Antigen Test (PSA)
7.3 Digital Rectal Exam (DRE)
8 Global Prostate Cancer Market, By End User
8.1 Introduction
8.2 Ambulatory Surgical Centers
8.3 Hospitals
8.4 Pharmacies
8.5 Specialty Clinics
8.6 Other End Users
9 Global Prostate Cancer Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Astellas, Inc.
11.2 AstraZeneca plc
11.3 Bristol Myers Squibb (BMS)
11.4 Johnson & Johnson
11.5 NOVARTIS
11.6 Sanofi S.A
11.7 TOLMAR Inc.
11.8 Tokai Pharmaceuticals
11.9 Progenics Pharmaceuticals Inc.
11.10 OncoGenex Pharmaceuticals Inc.
11.11 OncBioMune Pharmaceuticals Inc.
11.12 Endo Pharmaceuticals
11.13 Bayer Pharma AG
List of Tables
Table 1 Global Prostate Cancer Market Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Prostate Cancer Market Outlook, By Type (2016-2026) (US $MN)
Table 3 Global Prostate Cancer Market Outlook, By Hormone Sensitive (2016-2026) (US $MN)
Table 4 Global Prostate Cancer Market Outlook, By Hormone Refractory (2016-2026) (US $MN)
Table 5 Global Prostate Cancer Market Outlook, By Therapy (2016-2026) (US $MN)
Table 6 Global Prostate Cancer Market Outlook, By Focal Therapies (2016-2026) (US $MN)
Table 7 Global Prostate Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
Table 8 Global Prostate Cancer Market Outlook, By Cryosurgery (2016-2026) (US $MN)
Table 9 Global Prostate Cancer Market Outlook, By Immunotherapy (2016-2026) (US $MN)
Table 10 Global Prostate Cancer Market Outlook, By Vaccines (2016-2026) (US $MN)
Table 11 Global Prostate Cancer Market Outlook, By Therapeutic Vaccines (2016-2026) (US $MN)
Table 12 Global Prostate Cancer Market Outlook, By Provenge (Sipuleucel-T) (2016-2026) (US $MN)
Table 13 Global Prostate Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
Table 14 Global Prostate Cancer Market Outlook, By External Beam (2016-2026) (US $MN)
Table 15 Global Prostate Cancer Market Outlook, By Brachytherapy (2016-2026) (US $MN)
Table 16 Global Prostate Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
Table 17 Global Prostate Cancer Market Outlook, By Vinorelbine (2016-2026) (US $MN)
Table 18 Global Prostate Cancer Market Outlook, By Vinblastine (2016-2026) (US $MN)
Table 19 Global Prostate Cancer Market Outlook, By Taxotere (Docetaxel) (2016-2026) (US $MN)
Table 20 Global Prostate Cancer Market Outlook, By Taxanes (2016-2026) (US $MN)
Table 21 Global Prostate Cancer Market Outlook, By Jevtana (Cabazitaxel) (2016-2026) (US $MN)
Table 22 Global Prostate Cancer Market Outlook, By Etoposide (2016-2026) (US $MN)
Table 23 Global Prostate Cancer Market Outlook, By Cytotoxic Drugs (2016-2026) (US $MN)
Table 24 Global Prostate Cancer Market Outlook, By Carboplatin (2016-2026) (US $MN)
Table 25 Global Prostate Cancer Market Outlook, By Antimetabolites (2016-2026) (US $MN)
Table 26 Global Prostate Cancer Market Outlook, By Anthracyclines (2016-2026) (US $MN)
Table 27 Global Prostate Cancer Market Outlook, By Alkylating Agents (2016-2026) (US $MN)
Table 28 Global Prostate Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
Table 29 Global Prostate Cancer Market Outlook, By Trans Urethral Resection (TUR) (2016-2026) (US $MN)
Table 30 Global Prostate Cancer Market Outlook, By Radical Prostatectomy (2016-2026) (US $MN)
Table 31 Global Prostate Cancer Market Outlook, By Orchidectomy (2016-2026) (US $MN)
Table 32 Global Prostate Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
Table 33 Global Prostate Cancer Market Outlook, By Tyrosine Kinase Inhibitors (2016-2026) (US $MN)
Table 34 Global Prostate Cancer Market Outlook, By Signal Transduction Inhibitor (2016-2026) (US $MN)
Table 35 Global Prostate Cancer Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 36 Global Prostate Cancer Market Outlook, By Apoptosis Inducing Drugs (2016-2026) (US $MN)
Table 37 Global Prostate Cancer Market Outlook, By Angiogenesis Inhibitor (2016-2026) (US $MN)
Table 38 Global Prostate Cancer Market Outlook, By Bone Metastasis (2016-2026) (US $MN)
Table 39 Global Prostate Cancer Market Outlook, By Zometa (Zoledronic Acid) (2016-2026) (US $MN)
Table 40 Global Prostate Cancer Market Outlook, By Xofigo (Radium 223 Dichloride) (2016-2026) (US $MN)
Table 41 Global Prostate Cancer Market Outlook, By Xgeva (Denosumab) (2016-2026) (US $MN)
Table 42 Global Prostate Cancer Market Outlook, By Alpharadin (2016-2026) (US $MN)
Table 43 Global Prostate Cancer Market Outlook, By Hormonal Therapy (2016-2026) (US $MN)
Table 44 Global Prostate Cancer Market Outlook, By Aromatase Inhibitors (2016-2026) (US $MN)
Table 45 Global Prostate Cancer Market Outlook, By Estrogen-Receptor Modulators (Serms) (2016-2026) (US $MN)
Table 46 Global Prostate Cancer Market Outlook, By Luteinizing Hormone–Releasing Hormone (LHRH) Analogs (2016-2026) (US $MN)
Table 47 Global Prostate Cancer Market Outlook, By Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists (2016-2026) (US $MN)
Table 48 Global Prostate Cancer Market Outlook, By Anti–Androgens (2016-2026) (US $MN)
Table 49 Global Prostate Cancer Market Outlook, By Other Hormonal Therapies (2016-2026) (US $MN)
Table 50 Global Prostate Cancer Market Outlook, By Diagnostic Technique (2016-2026) (US $MN)
Table 51 Global Prostate Cancer Market Outlook, By Prostate Specific Antigen Test (PSA) (2016-2026) (US $MN)
Table 52 Global Prostate Cancer Market Outlook, By Digital Rectal Exam (DRE) (2016-2026) (US $MN)
Table 53 Global Prostate Cancer Market Outlook, By End User (2016-2026) (US $MN)
Table 54 Global Prostate Cancer Market Outlook, By Ambulatory Surgical Centers (2016-2026) (US $MN)
Table 55 Global Prostate Cancer Market Outlook, By Hospitals (2016-2026) (US $MN)
Table 56 Global Prostate Cancer Market Outlook, By Pharmacies (2016-2026) (US $MN)
Table 57 Global Prostate Cancer Market Outlook, By Specialty Clinics (2016-2026) (US $MN)
Table 58 Global Prostate Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
NOTE: Tables for North America, Europe, Asia Pacific, South America and Middle East & Africa are represented in the same manner above.


■ 説 明 ■

According to Stratistics MRC, the Global Prostate Cancer market is growing at a CAGR of 10.3% during the forecast period. Some of the key factors such as improved diagnosis and frequency rates in industrial economies, rapidly growing geriatric population, and the high demand for effective treatments are propelling the market growth. However, high price for treatment, lack of awareness and short accessibility of health care services in the small regions which are hampering the growth of the market.

Prostate cancer is one of the most ordinary types of cancer in men which is caused by the irregular growth of tissues in the prostate gland that produce seminal fluid. Various types of prostate cancer grow up slowly and may require minimal or no treatment, other types are hostile and can increase quickly. This needs novel drugs that will address the unmet desires low cost and enhanced survival time.

Based on Therapy, Biologic therapy is a treatment for patients with prostate cancer that involves utilize of existing organisms, substances plagiaristic from living organisms, or laboratory formed versions of living organisms. Biological therapies use diverse ways to rouse the immune system and stop tumor cells from rising. For patients with cancer, biological therapies may be used to treat the cancer itself or the side effects of other cancer treatments.

By Geography, Asia Pacific is expected to exhibit the utmost growth on account of the existence of untapped opportunity in the rising economies such as India and China. As well, rising healthcare expenditure has caused an increase in the implementation of technically advanced commodities, which is likely to boost county market growth.

Some of the key players profiled in the Prostate Cancer Market include Astellas, Inc., AstraZeneca plc, Bristol Myers Squibb (BMS), Johnson & Johnson, NOVARTIS, Sanofi S.A, TOLMAR Inc., Tokai Pharmaceuticals, Progenics Pharmaceuticals Inc., OncoGenex Pharmaceuticals Inc., OncBioMune Pharmaceuticals Inc., Endo Pharmaceuticals, and Bayer Pharma AG.

Types Covered:
• Hormone Sensitive
• Hormone Refractory

Therapies Covered:
• Focal Therapies
• Biologic Therapy
• Cryosurgery
• Immunotherapy
• Therapeutic Vaccines
• Radiation Therapy
• Chemotherapy
• Surgery
• Targeted Therapy
• Bone Metastasis
• Hormonal Therapy

Diagnostic Techniques Covered:
• Prostate Specific Antigen Test (PSA)
• Digital Rectal Exam (DRE)

End Users Covered:
• Ambulatory Surgical Centers
• Hospitals
• Pharmacies
• Specialty Clinics
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub-segments, and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
• Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances


グローバル市場調査データ販売概要

【レポートタイトル】世界の前立腺がん市場見通し2017-2026
【英語】Prostate Cancer - Global Market Outlook (2017-2026)

【発行日】2019年8月
【発行会社】Stratistics MRC
【商品コード】SMRC20FB306
【調査対象地域】グローバル
【販売サイト】GlobalResearch.jp

▼当市場調査データについて詳細内容・ご購入は下記ページへ▼
世界の前立腺がん市場見通し2017-2026...市場動向/規模/将来展望...



※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様

【キーワード】

世界の前立腺がん市場見通し2017-2026、市場動向、市場規模、将来展望